The incidence of thyroid cancer (TC) is increasing rapidly worldwide. The target therapy for papillary TC (PTC) is limited, and the studies of PTC prognostic biomarkers are not common. As a new member of annexin A (ANXA) family, the function and clinical significance of ANXA10 in PTC have not been well investigated.
Expressions of all the 12 ANXA members were detected with qPCR in 12 PTC tissues, and the ANXA10 mRNAs in PTCs and their adjacent normal thyroid tissues were compared. The subcellular location and expression of ANXA10 in 121 PTC patients were investigated with immunohistochemistry, which further classified the patients into subgroups with low or high ANXA10. The clinical significance and prognostic value of ANXA10 were estimated by analyzing its correlation with clinical factors and overall survival rates by the chi-squared test, univariate analyses, and multivariate analyses.
ANXA10 had the highest expression in PTCs among all the ANXA members. Moreover, ANXA10 was significantly upregulated in PTC compared with normal thyroid tissues. The PTC patients with low and high expression of ANXA10 took up 70.25% (85/121) and 29.75% (36/121), respectively. ANXA10 expression was associated with tumor size, differentiation, and overall survival rates of PTC. ANXA10 was an independent prognostic biomarker predicting the poor outcome of PTC.
ANXA10 expression was upregulated in PTC, and it was an independent prognostic biomarker of PTC, suggesting that ANXA10 may be a promising target for individual treatment of ANXA10.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Singh Ospina N, Iniguez-Ariza NM, Castro MR (2020) Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ 368:l6670. https://doi.org/10.1136/bmj.l6670
Kitahara CM, Sosa JA (2016) The changing incidence of thyroid cancer. Nat Rev Endocrinol 12:646–653. https://doi.org/10.1038/nrendo.2016.110
Vuong HG, Odate T, Duong UNP, Mochizuki K, Nakazawa T, Katoh R, Kondo T (2018) Prognostic importance of solid variant papillary thyroid carcinoma: a systematic review and meta-analysis. Head Neck 40:1588–1597. https://doi.org/10.1002/hed.25123
Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371. https://doi.org/10.1152/physrev.00030.2001
Gerke V, Creutz CE, Moss SE (2005) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6:449–461. https://doi.org/10.1038/nrm1661
Schloer S, Pajonczyk D, Rescher U (2018) Annexins in translational research: hidden treasures to be found. Int J Mol Sci 19. https://doi.org/10.3390/ijms19061781
Sharma M, Annexin C (2019) A2 (ANX A2): an emerging biomarker and potential therapeutic target for aggressive cancers. Int J Cancer 144:2074–2081. https://doi.org/10.1002/ijc.31817
Foo SL, Yap G, Cui J, Lim LHK (2019) Annexin-A1—a blessing or a curse in cancer? Trends Mol Med 25:315–327. https://doi.org/10.1016/j.molmed.2019.02.004
Liu XJ, Liu WL, Yang FM, Yang XQ, Lu XF (2015) Hepatoma-derived growth factor predicts unfavorable prognosis of epithelial ovarian cancer. Onco Targets Ther 8:2101–2109. https://doi.org/10.2147/OTT.S85660
Liu Z, Sun R, Zhang X, Qiu B, Chen T, Li Z, Xu Y, Zhang Z (2019) Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1. EBioMedicine 45:181–191. https://doi.org/10.1016/j.ebiom.2019.06.023
Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G, Sotiriou C (2015) RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 17:24. https://doi.org/10.1186/s13058-015-0538-7
Yeo W, Chan SL, Mo FKF, Chu CM, Hui JWY, Tong JHM, Chan AWH, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SCH (2015) Phase I/II study of temsirolimus for patients with unresectable hepatocellular carcinoma (HCC)—a correlative study to explore potential biomarkers for response. BMC Cancer 15:395. https://doi.org/10.1186/s12885-015-1334-6
Xu YF, Liu ZL, Pan C, Yang XQ, Ning SL, Liu HD, Guo S, Yu JM, Zhang ZL (2019) HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. Oncogene 38:868–880. https://doi.org/10.1038/s41388-018-0485-8
Raulf N, Lucarelli P, Thavaraj S, Brown S, Vicencio JM, Sauter T, Tavassoli M (2018) Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers. Eur J Cancer 102:52–68. https://doi.org/10.1016/j.ejca.2018.07.123
de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, Pardali E, le Devedec SE, Smit VT, van der Wal A, van't Veer LJ, Cleton-Jansen AM, ten Dijke P, van de Water B (2010) Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A 107:6340–6345. https://doi.org/10.1073/pnas.0913360107
Cheng TY, Wu MS, Lin JT, Lin MT, Shun CT, Huang HY, Hua KT, Kuo ML (2012) Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cancer 118:5757–5767. https://doi.org/10.1002/cncr.27565
van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA (2016) A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer 64:127–136. https://doi.org/10.1016/j.ejca.2016.06.003
Zhu J, Wu J, Pei X, Tan Z, Shi J, Lubman DM (2017) Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma. PLoS One 12:e0175039. https://doi.org/10.1371/journal.pone.0175039
Lu SH, Yuan RH, Chen YL, Hsu HC, Jeng YM (2013) Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. Histopathology 63:640–648. https://doi.org/10.1111/his.12229
Macaron C, Lopez R, Pai RK, Burke CA (2016) Expression of annexin A10 in serrated polyps predicts the development of metachronous serrated polyps. Clin Transl Gastroenterol 7:e205. https://doi.org/10.1038/ctg.2016.60
Sun R, Liu Z, Qiu B, Chen T, Li Z, Zhang X, Xu Y, Zhang Z (2019) Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. EBioMedicine 47:142–155. https://doi.org/10.1016/j.ebiom.2019.08.062
Perrier ND, Brierley JD, Tuttle RM (2018) Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68:55–63. https://doi.org/10.3322/caac.21439
Giordano T, Genomic J (2018) Hallmarks of thyroid neoplasia. Annu Rev Pathol 13:141–162. https://doi.org/10.1146/annurev-pathol-121808-102139
Bible KC, Ryder M (2016) Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol 13:403–416. https://doi.org/10.1038/nrclinonc.2016.19
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, X., Yang, M., Guo, Y. et al. Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer. Ir J Med Sci 190, 59–65 (2021). https://doi.org/10.1007/s11845-020-02263-x
- Annexin A10
- Papillary thyroid cancer